ElliotKeithChartashMD

Rheumatology • Rahway, NJ

Physician

Join to view full profile

Dr. Chartash is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chartash's full profile

Already have an account?

Office
126 East Scott Ave
Merck
Rahway, NJ 07065
Phone+1 732-594-3505

Education & Training

Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1982

Certifications & Licensure

NY State Medical License 1985 - 2020
NJ State Medical License 2005 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Fellow American College of Rheumatology

Publications & Presentations

PubMed

132 citations
First-in-human phase 1 study of the anti–TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non–small cell lung cancer
Jiaxin Niu, Corinne Maurice-Dror, Dongwhane Lee, Dai Woo Kim, Adnan Nagrial
Annals of Oncology. 2021-11-17
26 citations
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors.
Kyriakos P. Papadopoulos, Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash
Clinical Cancer Research. 2021-04-01
1 citations
Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020)...
Mallika Lala, Tommy Ruosi Li, Dinesh P. de Alwis, Vikram Sinha, Kapil Mayawala
European Journal of Cancer. 2021-01-04